We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine
News

Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine

Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine
News

Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

“We are very pleased to gain this important intellectual property protection that strengthens our SysDx approach to understanding a patient’s disease and predicting response or non-response to a therapy,” said David de Graaf, CEO of Selventa. “This patent is a significant step forward in the development of SysDx tests in multi-factorial diseases such as rheumatoid arthritis, IBD, and cancer. It also strengthens our leadership position in analyzing ‘big data’ molecular information to identify patient disease-relevant biomarkers.”

A major differentiator of SysDx tests is their ability to incorporate and analyze ALL relevant molecular information in a disease, across thousands of patients, to identify biomarkers that are linked to disease-driving mechanisms.

“In order to deliver true personalized medicine, physicians will require diagnostics that holistically integrate and interpret multiple types of biological data. SysDx tests consist of biomarkers that are selected through a rigorous biomarker analysis of a patient’s biological map derived from large, multi-omic data sets that can include genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medial record information. This comprehensive analysis is then used to generate a clinically-relevant diagnostic report that physicians and patients can use to make an optimal treatment decision,” concluded de Graaf.

Advertisement